Zymeworks Licenses ZW209 to Roche With $55 Million Upfront
Zymeworks will receive $55 million upfront and may earn milestone payments and royalties as Roche takes global development rights to ZW209.
Makkler Newsroom · Oct 23, 06:54 PM · 1 min read
Zymeworks Inc. ZYME
NASDAQHealth TechnologyUnited States
$26.24-0.23 (-0.87%)
Market closed· · USD · Data may be delayed
- Day's range
- 25.8226.75
- 52-week range
- 21.5231.97
Financial health
– / 5
Analyst view · 14 firms
Buy14 buy · 0 hold · 0 sell
Avg. target $43.29 (+65.0%)
Prices may be delayed and are for informational purposes only - not investment advice.